Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Galan, 2021
 
RBR-8h7q82
RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
53/115 suggested
  • inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
Galan, 2021
 
RBR-8h7q82
RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
53/115 suggested
  • inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
Niaee (vs placebo), 2020
 
IRCT20200408046987N1
RCTivermectincontrolCOVID-19 severe or criticallyhigh
120/30 suggested
  • suggested 86 % decrease in deaths but with a low degree of certainty due to high risk of bias
Okumuş, 2020
 
NCT04646109
RCTivermectincontrolCOVID-19 severe or criticallyhigh
30/30 inconclusive
    Camprubi, 2020 OBSivermectinstandard of careCOVID-19 severe or criticallyNA
    13/13 inconclusive

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).